Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash & Equivalents (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Cash & Equivalents data on record, last reported at $8.3 million in Q2 2025.

  • For Q2 2025, Cash & Equivalents fell 2.33% year-over-year to $8.3 million; the TTM value through May 2025 reached $8.3 million, down 2.33%, while the annual FY2025 figure was $8.3 million, 2.33% down from the prior year.
  • Cash & Equivalents reached $8.3 million in Q2 2025 per LFCR's latest filing, up from $5.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $19.1 million in Q2 2023 and bottomed at $609000.0 in Q4 2021.
  • Average Cash & Equivalents over 5 years is $5.2 million, with a median of $3.6 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: crashed 75.4% in 2021, then soared 1826.44% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $609000.0 in 2021, then skyrocketed by 1016.58% to $6.8 million in 2022, then soared by 180.75% to $19.1 million in 2023, then plummeted by 50.47% to $9.5 million in 2024, then decreased by 12.59% to $8.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $8.3 million in Q2 2025, $5.4 million in Q1 2025, and $9.5 million in Q4 2024.